0001193125-12-303586.txt : 20120716 0001193125-12-303586.hdr.sgml : 20120716 20120716171823 ACCESSION NUMBER: 0001193125-12-303586 CONFORMED SUBMISSION TYPE: SC 14D9/A PUBLIC DOCUMENT COUNT: 7 FILED AS OF DATE: 20120716 DATE AS OF CHANGE: 20120716 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: HUMAN GENOME SCIENCES INC CENTRAL INDEX KEY: 0000901219 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 223178468 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 14D9/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-45295 FILM NUMBER: 12964268 BUSINESS ADDRESS: STREET 1: 14200 SHADY GROVE ROAD CITY: ROCKVILLE STATE: MD ZIP: 20850-3338 BUSINESS PHONE: 3013098504 MAIL ADDRESS: STREET 1: 14200 SHADY GROVE ROAD CITY: ROCKVILLE STATE: MD ZIP: 20850 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: HUMAN GENOME SCIENCES INC CENTRAL INDEX KEY: 0000901219 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 223178468 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 14D9/A BUSINESS ADDRESS: STREET 1: 14200 SHADY GROVE ROAD CITY: ROCKVILLE STATE: MD ZIP: 20850-3338 BUSINESS PHONE: 3013098504 MAIL ADDRESS: STREET 1: 14200 SHADY GROVE ROAD CITY: ROCKVILLE STATE: MD ZIP: 20850 SC 14D9/A 1 d367209dsc14d9a.htm AMENDMENT #11 Amendment #11

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14D-9

Solicitation/Recommendation Statement under Section 14(d)(4)

of the Securities Exchange Act of 1934

(Amendment No. 11)

 

 

HUMAN GENOME SCIENCES, INC.

(Name of Subject Company)

 

 

HUMAN GENOME SCIENCES, INC.

(Name of Person Filing Statement)

Common Stock, $0.01 par value per share

(Title of Class of Securities)

444903108

(CUSIP Number of Class of Securities)

James H. Davis

Executive Vice President, General Counsel and Secretary

14200 Shady Grove Road

Rockville, Maryland 20850-7464

(301) 309-8504

(Name, address and telephone number of person authorized to receive notices and communications on behalf of the person filing statement)

 

 

With copies to:

 

Michael P. Rogan

Marc S. Gerber

Skadden, Arps, Slate, Meagher & Flom LLP

1440 New York Avenue, NW

Washington, D.C. 20005

(202) 371-7000

  

Robert W. Smith, Jr.

Jason C. Harmon

DLA Piper LLP (US)

6225 Smith Avenue

Baltimore, Maryland 21209
(410) 580-3000

 

 

 

¨ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

 

 

 

Introduction

This Amendment No. 11 to the Schedule 14D-9 (the “Amendment”) amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 (as amended from time to time, the “Statement”) originally filed by Human Genome Sciences, Inc., a Delaware corporation (“HGS” or the “Company”), with the Securities and Exchange Commission (the “SEC”) on May 17, 2012.

Except as otherwise set forth in this Amendment, the information set forth in the Statement remains unchanged and is incorporated herein by reference as relevant to the items in this Amendment. Capitalized terms used but not defined herein have the meanings ascribed to them in the Statement.

Item 9. Exhibits

Item 9 of the Statement is hereby amended and supplemented by adding the following exhibits:

 

Exhibit
No.		   Description
(a)(21)   Press Release, dated July 16, 2012.
(a)(22)   Letter to the Company’s employees re: GSK and HGS Announcement of Merger, dated July 16, 2012.
(a)(23)   HGS-GSK Acquisition FAQ for Employees, dated July 16, 2012.
(a)(24)   Transcript of video statement to the Company’s Employees on July 16, 2012.

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

HUMAN GENOME SCIENCES, INC.
By:  

/s/ James H. Davis

Name:   James H. Davis
Title:  

Executive Vice President,

General Counsel and Secretary

Dated: July 16, 2012

EX-99.A.21 2 d367209dex99a21.htm EXHIBIT (A)(21) Exhibit (a)(21)

Exhibit (a)(21)

 

LOGO

Issued: Monday 16 July 2012, London UK – LSE announcement

GSK to acquire Human Genome Sciences for US$14.25 per share in cash

 

•  

GSK to acquire full ownership of BENLYSTA®, albiglutide and darapladib

 

•  

Acquisition will be accretive to GSK core earnings in 2013

 

•  

Tender offer amended to US$14.25 per share and extended until 27 July 2012

 

 

GlaxoSmithKline plc (LSE: GSK) and Human Genome Sciences (NASDAQ: HGSI) today announced that the companies have entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in cash. The transaction values HGS at approximately US$3.6 billion on an equity basis, or approximately US$3 billion net of cash and debt, and represents a premium of 99% to the HGS closing price of US$7.17 per share on 18 April 2012, the last day of trading before HGS publicly disclosed GSK’s initial private offer. The Boards of Directors of both companies have approved the transaction.

The transaction is well aligned with GSK’s long-term strategy of delivering sustainable growth, simplifying GSK’s business model, enhancing R&D returns and deploying capital with discipline. Through complete ownership of BENLYSTA, albiglutide and darapladib, GSK can simplify and optimize R&D, commercial and manufacturing operations to advance these products most effectively and efficiently while securing the full potential long-term value of the assets. GSK expects to achieve at least US$200 million in cost synergies to be fully realized by 2015, subject to appropriate consultation, and expects the transaction to be accretive to core earnings beginning in 2013. GSK also assessed the potential returns of this acquisition relative to its long-term share buyback program. As part of this ongoing program, GSK continues to expect to repurchase £2-2.5 billion in shares in 2012.

Sir Andrew Witty, Chief Executive Officer of GSK, said: “We are pleased to have reached a mutually beneficial agreement with HGS on friendly terms and believe the combination of GSK and HGS represents clear financial and strategic logic for both companies and our respective shareholders. The transaction meets GSK’s strict financial criteria for acquisitions, and we expect will deliver significant returns over the long-term. This is a natural next step in our nearly 20-year relationship with HGS, and we look forward to working with HGS to integrate our businesses and to realizing the full value of BENLYSTA, albiglutide, and darapladib for the benefit of patients and our shareholders.”

H. Thomas Watkins, President and Chief Executive Officer, HGS, said: “After a thorough analysis of strategic alternatives, HGS has determined that a combination with GSK is the best course of action for our company and the best way to maximize value for our stockholders. HGS has had a long and productive working relationship with GSK, and together we will be uniquely positioned to achieve the full potential of BENLYSTA and other products in our pipeline for the benefit of those battling serious disease around the world. I would like to thank the dedicated employees of HGS, who have worked tirelessly to achieve breakthrough results and are the foundation of our success. We look forward to working with GSK to ensure a seamless transition for all of our stakeholders.”

LOGO

GSK has amended its pending tender offer to increase the price to US$14.25 per share and to extend the expiration of the offer to 12:00 midnight, New York City time, on 27 July 2012. As of the close of business on 13 July, approximately 427,042 shares had been tendered and not withdrawn, pursuant to the offer. The offer is subject to customary conditions as set forth in the Merger Agreement being filed today by the parties with the SEC.

Lazard and Morgan Stanley are acting as financial advisors to GSK, and Cleary Gottlieb Steen & Hamilton and Wachtell, Lipton, Rosen & Katz are providing legal advice to the company. Goldman, Sachs & Co. and Credit Suisse Securities (USA) LLC are serving as financial advisors to HGS, and Skadden, Arps, Slate, Meagher & Flom LLP and DLA Piper LLP (US) are serving as legal counsel.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

Human Genome Sciences – exists to place new therapies into the hands of those battling serious disease. For more information about HGS, please visit the Company’s web site at www.hgsi.com. HGS, Human Genome Sciences and BENLYSTA® are trademarks of Human Genome Sciences, Inc. Other trademarks referenced are the property of their respective owners.

 

GlaxoSmithKline Enquiries:   
UK Media enquiries:    David Mawdsley    +44(0) 20 8047 5502    (London)
   Sarah Spencer    +44(0) 20 8047 5502    (London)
Analyst/Investor enquiries:    Sally Ferguson    +44(0) 20 8047 5543    (London)
   Tom Curry    +1 215 751 5419    (Philadelphia)
   Gary Davies    +44(0) 20 8047 5503    (London)
   Jeff McLaughlin    +1 215 751 7002    (Philadelphia)
   Ziba Shamsi    +44(0) 20 8047 3289    (London)
   James Dodwell    +44(0) 20 8047 2406    (London)
Sard Verbinnen & Co:
US Media enquiries    George Sard    +1 212 687 8080    (New York)
   Andrew Cole    +1 212 687 8080    (New York)
   Michael Henson    +1 212 687 8080    (New York)

Human Genome Sciences Enquiries:

Media:

Susannah Budington

Director, Corporate Public Relations

301-545-1062

Jerry Parrott

Vice President, Corporate Communications

301-315-2777

Investor Contact:

Claudine Prowse, Ph.D.

Vice President, Investor Relations

301-610-5800

Additional Contacts:

Joele Frank / Dan Katcher / Jamie Moser Joele Frank, Wilkinson Brimmer Katcher

(212) 355-4449

Arthur Crozier / Jennifer Shotwell / Larry Miller Innisfree M&A Incorporated

(212) 750-5833

 

Page 2

LOGO

Cautionary statement regarding forward-looking statements

This communication contains forward-looking statements. GSK cautions readers that any forward-looking statements made by GSK, including those made in this communication, are subject to risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Such forward-looking statements include, but are not limited to, statements about the benefits of a business combination transaction involving GSK and HGS, including future financial and operating results, GSK’s plans, objectives, expectations (financial or otherwise) and intentions relating to the business combination and other statements that are not historical facts. Factors that may affect GSK’s operations are described under ‘Risk factors’ in the ‘Financial review & risk’ section in GSK’s Annual Report 2011 included as exhibit 15.2 to GSK’s Annual Report on Form 20-F for 2011.

This announcement includes statements that are forward-looking. These forward-looking statements are based on HGS’s current intentions, beliefs and expectations regarding future events. HGS cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from HGS’s expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this announcement, and, except as required by law, HGS does not undertake to update any forward-looking statement to reflect new information, events or circumstances. Some important factors that could cause HGS’s actual results to differ from its expectations in these forward-looking statements include: HGS’s lack of commercial experience and dependence on the sales growth of BENLYSTA; any failure to commercialize BENLYSTA successfully; the occurrence of adverse safety events with HGS’s products; changes in the availability of reimbursement for BENLYSTA; the inherent uncertainty of the timing, success of, and expense associated with, research, development, regulatory approval and commercialization of HGS’s pipeline products, including darapladib and albiglutide, and new indications for existing products; uncertainty as to the future success of darapladib and GSK’s ability to develop and commercialize darapladib; substantial competition in HGS’s industry, including from branded and generic products; the highly regulated nature of HGS’s business; uncertainty regarding HGS’s intellectual property rights and those of others; the ability to manufacture at appropriate scale, and in compliance with regulatory requirements, to meet market demand for HGS’s products; HGS’s substantial indebtedness and lease obligations; HGS’s dependence on collaborations over which it may not always have full control; foreign exchange rate valuations and fluctuations; the impact of HGS’s acquisitions and strategic transactions; changes in the health care industry in the U.S. and other countries, including government laws and regulations relating to sales and promotion, reimbursement and pricing generally; significant litigation adverse to HGS, including product liability and patent infringement claims; HGS’s ability to attract and retain key personnel; increased scrutiny of the health care industry by government agencies and state attorneys general resulting in investigations and prosecutions; risks and uncertainties associated with the merger agreement and related tender offer by GSK and; the outcome of any litigation related to the merger agreement and related tender offer by GSK. The foregoing list sets forth many, but not all, of the factors that could cause actual results to differ from HGS’s expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in HGS’s periodic reports filed with the SEC, when evaluating HGS’s forward-looking statements.

This announcement is for informational purposes only and does not constitute an offer to purchase or a solicitation of an offer to sell HGS common stock. The solicitation and offer to buy HGS common stock, commenced by GlaxoSmithKline plc through its wholly owned subsidiary, H. Acquisition Corp., have been made pursuant to an offer to purchase and related materials, filed on Schedule TO with the U.S. Securities and Exchange Commission (SEC), as amended and as will be further amended from time to time. In response to the offer, HGS has filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC, as amended and as will be further amended from time to time. Investors and securityholders are urged to read these materials carefully since they contain important information, including the terms and conditions of the offer. Investors and security holders may obtain free copies of these materials and other documents filed by GSK and HGS with the SEC at the website maintained by the SEC as www.sec.gov. The offer to purchase and related materials may also be obtained for free by contacting the information agent for the tender offer, D.F. King & Co., Inc. at (212) 269-5550 or (800) 848-2998 (toll-free) or by email at HGStender@dfking.com. HGS will also provide a copy of the solicitation/recommendation statement materials without charge on its website at www.hgsi.com, or HGS stockholders may call HGS’ Information Agent, Innisfree M&A Incorporated, toll-free at 877-717-3926.

Registered in England & Wales:

No. 3888792

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

 

Page 3

EX-99.A.22 3 d367209dex99a22.htm EXHIBIT (A)(22) Exhibit (a)(22)

Exhibit (a)(22)

Subject: GSK and HGS Announce Agreement

Dear HGS Colleagues,

Today marks a milestone in HGS history. Earlier today, we announced that we have entered into an agreement under which GSK will acquire all of the outstanding shares of HGS common stock for $14.25 per share in cash, or $3.6 billion on an equity basis. This transaction is a testament to all that you have achieved and marks a turning point for all of us. Attached for your reference is a copy of the press release.

GSK is a leading global healthcare company, with a history of treating major diseases dating back to the eighteenth century. Its mission is to improve the quality of human life by enabling people to do more, feel better and live longer. As you know, HGS has had a long and productive working relationship with GSK. We are confident that our assets and many of our people will become part of GSK, thrive, and do much good for patients – including realizing the full potential of BENLYSTA and other products in our pipeline for the benefit of those battling serious disease around the world.

Having conducted a thorough analysis of our strategic alternatives, the HGS Board and management team have concluded that this transaction is the right decision for our company. As part of GSK, we will have access to greater resources and growth opportunities. HGS employees who are also stockholders will also benefit from the premium to be paid for HGS shares.

As you can appreciate, we are in the early stages of this process and there is still a lot of work to be done in the days ahead. Given the history of our companies, we anticipate a smooth integration. As we have more information about the transition and integration plans in the coming weeks, we will provide you with an update. As always, we are committed to treating employees fairly and we are committed to keeping you updated on important developments.

We expect the transaction to close in the next few weeks, subject to customary closing conditions and successful completion of a tender offer for HGS shares. Until that time, HGS and GSK will continue to operate as independent companies, and we need you to attend to our ongoing priorities at HGS. The most important thing for you to do is to continue to perform your job with the same level of dedication, focus and excellence as always.

It is likely that today’s news will lead to increased interest in HGS, and it is important we speak with one voice. Questions from investors should be referred to Claudine Prowse at claudine_prowse@hgsi.com or 301-315-1785. If you receive inquiries from the media or other interested parties, please refer them to Jerry Parrott at jerry_parrott@hgsi.com or 301-315-2727. We will make every effort to keep you informed throughout this process with periodic updates.

Thank you for all you do, and have done, to make our company successful. I am very proud of the progress that HGS has made since our founding in 1992, and I would like to thank each of you for your hard work and dedication. We have built a great company and the breakthrough results we have achieved enhance the lives of thousands of people around the world. I hope you will join me in embracing the new opportunities that lay ahead of us.

Watch for an invitation to an All Employee Meeting that we will hold later this week – it will be an opportunity to honor you and to discuss what you can expect from here.

Regards,

Tom

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This announcement includes statements that are forward-looking. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this announcement, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.

Some important factors that could cause our actual results to differ from our expectations in these forward-looking statements include: our lack of commercial experience and dependence on the sales growth of BENLYSTA; any failure to commercialize BENLYSTA successfully; the occurrence of adverse safety events with our products; changes in the availability of reimbursement for BENLYSTA; the inherent uncertainty of the timing, success of, and expense associated with, research, development, regulatory approval and commercialization of our pipeline products, including darapladib and albiglutide, and new indications for existing products; uncertainty as to the future success of darapladib and GSK’s ability to develop and commercialize darapladib; substantial competition in our industry, including from branded and generic products; the highly regulated nature of our business; uncertainty regarding our intellectual property rights and those of others; the ability to manufacture at appropriate scale, and in compliance with regulatory requirements, to meet market demand for our products; our substantial indebtedness and lease obligations; our dependence on collaborations over which we may not always have full control; foreign exchange rate valuations and fluctuations; the impact of our acquisitions and strategic transactions; changes in the health care industry in the U.S. and other countries, including government laws and regulations relating to sales and promotion, reimbursement and pricing generally; significant litigation adverse to the Company, including product liability and patent infringement claims; our ability to attract and retain key personnel; increased scrutiny of the health care industry by government agencies and state attorneys general resulting in investigations and prosecutions; risks and uncertainties associated with the merger agreement and related tender offer by GSK; and the outcome of any litigation related to the merger agreement and related tender offer by GSK.

The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the SEC, when evaluating our forward-looking statements.

IMPORTANT INFORMATION FOR INVESTORS AND STOCKHOLDERS

This communication does not constitute an offer to buy or a solicitation of an offer to sell any securities. In response to the amended tender offer commenced by GlaxoSmithKline plc through its wholly owned subsidiary, H. Acquisition Corp., HGS will file an amendment to its solicitation/recommendation statement on Schedule 14D-9 with the SEC. INVESTORS AND STOCKHOLDERS OF HGS ARE URGED TO READ THE SOLICITATION/RECOMMENDATION STATEMENT, AND ANY AMENDMENTS OR SUPPLEMENTS THERETO, AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Investors and stockholders may obtain a copy of these documents free of charge at the SEC’s website at www.sec.gov. HGS also will provide a copy of these materials without charge on its website at www.hgsi.com, or stockholders may call HGS’ Information Agent, Innisfree M&A Incorporated, toll-free at 877-717-3926.

EX-99.A.23 4 d367209dex99a23.htm EXHIBIT (A)(23) Exhibit (a)(23)

Exhibit (a)(23)

16 July 2012

HGS - GSK Acquisition FAQ for Employees

 

 

1. What did HGS announce today?

Today we announced that GSK and HGS have entered into an agreement under which GSK will acquire all of the outstanding shares of HGS common stock for $14.25 per share in cash, or $3.6 billion on an equity basis. This means that if all the conditions to the transaction are satisfied, HGS would become a part of GSK’s business, and its stock would cease trading on the NASDAQ.

 

2. Why are you doing this transaction?

Having conducted a thorough analysis of our strategic alternatives, the HGS Board and management team have concluded that this transaction is the right decision for our company as it maximizes value for the stockholders. HGS has had a long and productive working relationship with GSK. We are confident that our assets and many of our people will become part of GSK, thrive, and do much good for patients – including realizing the full potential of BENLYSTA and other products in our pipeline for the benefit of those battling serious disease around the world.

 

3. What other options/deals did the Board consider?

We completed a thorough process and determined that this is the best decision for our company as it maximizes value for the stockholders.

 

4. How will this transaction benefit employees?

This transaction is a testament to the many accomplishments of HGS’ valued employees. HGS employees have done an excellent job in building HGS to where it is today. As part of GSK, we will have access to even greater resources and growth opportunities, and together with GSK we can take our products to the next level. HGS employees who are also stockholders will also benefit from the premium to be paid for HGS shares.

 

5. What happens now? How will my job and my benefits be affected?

Until the transaction is completed, which we expect in the next few weeks, HGS and GSK will continue to operate as independent companies, and HGS employees will need to attend to our ongoing priorities. As you can appreciate, we are in the early stages of this process and there is still a lot of work to be done in the days ahead. Given the history of our companies, we anticipate a smooth integration. As we have more information about the transition and integration plans – and your benefits – in the coming weeks, we will provide you with an update. As always, we are committed to treating employees fairly and we are committed to keeping you updated on important developments.

Three specific benefits-related issues are addressed in the agreement, which will be posted publicly today. They are:

 

  •  

The HGS health and welfare plans will remain intact through Dec. 31, 2012. From January 1 to December 31, 2013, GSK will provide current HGS employees who remain employed following the closing benefits that are comparable (in the aggregate) to those provided by HGS immediately prior to the closing of the deal or, at GSK’s option, benefits provided by GSK under its plans to similarly situated employees.

 

1

16 July 2012

HGS - GSK Acquisition FAQ for Employees

 

 

  •  

Our employees generally will be credited with their pre-closing HGS service for GSK benefits plan purposes.

 

  •  

GSK will honor all HGS benefit plans and compensation arrangements, including severance arrangements and any right or benefit arising as a result of the merger, in effect before the closing in accordance with their terms.

Finally, the press release references “at least $200 million in cost synergies … by 2015.” While it is likely that some of these savings will come in the form of jobs, what functions and who is likely to be affected will be uncertain for some period of time, perhaps months. We will keep you updated as plans develop.

 

6. What should I say if our external customers ask me about the transaction? Why is this good for them?

Until the transaction is closed, today’s announcement will have no impact on our customers or how we conduct business with them. We are counting on you to continue to perform your job with the same level of dedication, focus and excellence as always.

 

7. What approvals are needed to complete the merger? What is the timeframe for closing?

The transaction is expected to be completed in the next few weeks. It is subject to the satisfaction of customary closing conditions, including the successful completion of a tender offer for HGS shares. Until the transaction closes, we will continue to operate as two independent companies.

 

8. Should I, or can I, sell HGS stock that I own or exercise HGS stock options and restricted stock units?

The Company had previously imposed a trading blackout for employees. We will be providing further direction about HGS shares, options and restricted stock units in the coming days.

 

9. What should we say if we are contacted by media, financial community, or other third parties about the proposal?

Consistent with company policy, questions from investors should be referred to Claudine Prowse at claudine_prowse@hgsi.com or 301-315-1785. If you receive inquiries from the media or other interested parties, please refer them to Jerry Parrott at jerry_parrott@hgsi.com or 301-315-2727.

 

10. Who can I contact if I have more questions?

As we move through this process, we will keep you informed on important developments by email or postings to the intranet homepage. We can anticipate many of your questions, and will be working on answers in the days to come.

 

2

16 July 2012

HGS - GSK Acquisition FAQ for Employees

 

 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This announcement includes statements that are forward-looking. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this announcement, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.

Some important factors that could cause our actual results to differ from our expectations in these forward-looking statements include: our lack of commercial experience and dependence on the sales growth of BENLYSTA; any failure to commercialize BENLYSTA successfully; the occurrence of adverse safety events with our products; changes in the availability of reimbursement for BENLYSTA; the inherent uncertainty of the timing, success of, and expense associated with, research, development, regulatory approval and commercialization of our pipeline products, including darapladib and albiglutide, and new indications for existing products; uncertainty as to the future success of darapladib and GSK’s ability to develop and commercialize darapladib; substantial competition in our industry, including from branded and generic products; the highly regulated nature of our business; uncertainty regarding our intellectual property rights and those of others; the ability to manufacture at appropriate scale, and in compliance with regulatory requirements, to meet market demand for our products; our substantial indebtedness and lease obligations; our dependence on collaborations over which we may not always have full control; foreign exchange rate valuations and fluctuations; the impact of our acquisitions and strategic transactions; changes in the health care industry in the U.S. and other countries, including government laws and regulations relating to sales and promotion, reimbursement and pricing generally; significant litigation adverse to the Company, including product liability and patent infringement claims; our ability to attract and retain key personnel; increased scrutiny of the health care industry by government agencies and state attorneys general resulting in investigations and prosecutions; risks and uncertainties associated with the merger agreement and related tender offer by GSK; and the outcome of any litigation related to the merger agreement and related tender offer by GSK.

The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the SEC, when evaluating our forward-looking statements.

IMPORTANT INFORMATION FOR INVESTORS AND STOCKHOLDERS

This communication does not constitute an offer to buy or a solicitation of an offer to sell any securities. In response to the amended tender offer commenced by GlaxoSmithKline plc through its wholly owned subsidiary, H. Acquisition Corp., HGS will file an amendment to its solicitation/recommendation statement on Schedule 14D-9 with the SEC. INVESTORS AND STOCKHOLDERS OF HGS ARE URGED TO READ THE

 

3

16 July 2012

HGS - GSK Acquisition FAQ for Employees

 

 

SOLICITATION/RECOMMENDATION STATEMENT, AND ANY AMENDMENTS OR SUPPLEMENTS THERETO, AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Investors and stockholders may obtain a copy of these documents free of charge at the SEC’s website at www.sec.gov. HGS also will provide a copy of these materials without charge on its website at www.hgsi.com, or stockholders may call HGS’ Information Agent, Innisfree M&A Incorporated, toll-free at 877-717-3926.

 

4

EX-99.A.24 5 d367209dex99a24.htm EXHIBIT (A)(24) Exhibit (a)(24)

Exhibit (a)(24)

Good afternoon everyone.

As you know, earlier today we announced our agreement with GlaxoSmithKline under which they will acquire the company. This is likely to be something completed over the next few weeks and I wanted to give you just a touch of perspective on this announcement before we meet later this week on Thursday at our company meeting to talk more about this.

Let me start with this. Everybody in this company has had an enormous role in the significant accomplishments of HGS. As you know we’re just, almost, we’re a touch shy of our 20th anniversary. And when I look at the accomplishments of this company, particularly over the last few years, but really throughout our history, they are enormous.

I can tell you our GSK soon to be parent looks at it very much the same way. They are enormously impressed with the great work that’s been done here, and they view, and I’d like to make sure we view, this as a positive step that can mean new opportunities for the work we do, for the people around here, and for things we can do together going forward.

So, you all know there is a lot we don’t know yet about specifics, and that’s understandable and logical. We’ll learn more about many of those uncertainties and things will begin to become clarified in the future here.

I just want to tell all of you how enormously pleased and quite honestly appreciative we are of the terrific work you’ve done and we look forward to exploring what these new opportunities can and will be together in the coming days and weeks.

Thank you very much.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This announcement includes statements that are forward-looking. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this announcement, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.

Some important factors that could cause our actual results to differ from our expectations in these forward-looking statements include: our lack of commercial experience and dependence on the sales growth of BENLYSTA; any failure to commercialize BENLYSTA successfully; the occurrence of adverse safety events with our products; changes in the availability of reimbursement for BENLYSTA; the inherent uncertainty of the timing, success of, and expense associated with, research, development, regulatory approval and commercialization of our pipeline products, including darapladib and albiglutide, and new indications for existing products; uncertainty as to the future success of darapladib and GSK’s ability to develop and commercialize darapladib; substantial competition in our industry, including from branded and generic products; the highly regulated nature of our business; uncertainty regarding our intellectual property rights and those of others; the ability to manufacture at appropriate

scale, and in compliance with regulatory requirements, to meet market demand for our products; our substantial indebtedness and lease obligations; our dependence on collaborations over which we may not always have full control; foreign exchange rate valuations and fluctuations; the impact of our acquisitions and strategic transactions; changes in the health care industry in the U.S. and other countries, including government laws and regulations relating to sales and promotion, reimbursement and pricing generally; significant litigation adverse to the Company, including product liability and patent infringement claims; our ability to attract and retain key personnel; increased scrutiny of the health care industry by government agencies and state attorneys general resulting in investigations and prosecutions; risks and uncertainties associated with the merger agreement and related tender offer by GSK; and the outcome of any litigation related to the merger agreement and related tender offer by GSK.

The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the SEC, when evaluating our forward-looking statements.

IMPORTANT INFORMATION FOR INVESTORS AND STOCKHOLDERS

This communication does not constitute an offer to buy or a solicitation of an offer to sell any securities. In response to the amended tender offer commenced by GlaxoSmithKline plc through its wholly owned subsidiary, H. Acquisition Corp., HGS will file an amendment to its solicitation/recommendation statement on Schedule 14D-9 with the SEC. INVESTORS AND STOCKHOLDERS OF HGS ARE URGED TO READ THE SOLICITATION/RECOMMENDATION STATEMENT, AND ANY AMENDMENTS OR SUPPLEMENTS THERETO, AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Investors and stockholders may obtain a copy of these documents free of charge at the SEC’s website at www.sec.gov. HGS also will provide a copy of these materials without charge on its website at www.hgsi.com, or stockholders may call HGS’ Information Agent, Innisfree M&A Incorporated, toll-free at 877-717-3926.

GRAPHIC 6 g367209g56s67.jpg GRAPHIC begin 644 g367209g56s67.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`/P+&`P$1``(1`0,1`?_$`*```0`!`P4!```````` M```````(!@<)`0,$!0H"`0$``04!`0$!`````````````0(&!P@)!0,$"A`` M``8"`@$#!`$!!@,L*\N5>1+-*B_6C M9Z5S\-OFNVF_8XYR7HLJ-7^GVI?XE^<'[?\`6G8UM%HL1V_BT^YG/(C0JR:J MPH9MQU)1(73VD&S0PM11*+CCD*`[:XR3'<=;CNY!?TM$U+4M$5RXM M8-8W)6VDEK1'7-?82\I"#(S)/)D1\@#8I\NQ/(7W8M!D^/7DEEKWWH]/=5MF M^TSYI1[SK4*2^XVUYJ(O(R(N3(@!\5^9X?;75AC55E>-V>1U*/=M:"OO:N;= M5C1+0V;EA51I3DZ$CS<2GEQM):X;AR8J\NRW&<61.<-F$O([ZJ MHTS'2]3:BJLY<4I#A%_VHY,`5#'D,2F&9,5YJ3&D-H>8D1W$/,/LN));;K+K M:E-N-N(,C2I)F1D?)`#=```````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````%F]^;UP'KAJS)=M[(GN0LYWEY..)97A:RG)Z1A%>LI/1?Q>B9?_`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`,6[=7FY\OQ;!*/ M*9VS,HJ\?9R"BQZZ9:I&,,?/VT/26F69:HQGY*(E"M^?()O]Y],;2PWKA\0V MCM@R:_LQL=P)-9-50-5$^/6,V:76UKCLI M>)1M^ZK6YK]GVN4*?*N+:]=-M;R%?81E$-\EO-*CP7'6R4XE"_$ MR5+UK0@DWWHZI;HRON/L;>M%IK7/R&:P=QK&Z&UTE9[2M,?SO0ZX<1?NPJ:@ MQ[):=R.YXQ$=::4?*!1+R M29`1```````````````````````````````````````````````````````` M``````````````````````````````````````````````````//5\\>ULEJ ML?TAIB"^VQBN:2\BS?(F?QV%O3YV&O5,.B9.0XA3[#,5^[<>,FS1YK)/D9D7 M`U7_`":YK,LX7'N*BK)VG%05?*2)F]4Q>0RN&X["MWYY7)P M4JJ:=4[URQMVM)0?N6V]S;6UKP8AYSN7(\?C]DY/E+N-#!X.]*UM=N22:QK. M6I[HRE*XO9O);=JEO3\I:]["D4420=/"W.W*W[BW/5W&FU"JK2*]&U5?J?BO6N2 MO6UERN6[ENZK;VK16TXISHZ5D]:I-)_H9#]N1YEKCG6DF2\8$?K+@2[&Q61? MBP&UVV3K2AUY1^VTZII)J2E1EPG[C]!>_P`T=6S.PX_1+EM26'8Z+QZN7/Z+ M?^ME.C?A-K5)M::O0U7Z%?Q\#ENX[W7*GW+-]NVOYIM6L=526K5=&UZZ>2"> M=V-8Y)FIJU.+AI<-+#CI\J<0DDI-1>A&25+(S(SX/QX&%\3$QX9;AA[GCJ7V MM^:4_P"M6;*]$_I_"G[S()\0-<^[N3;-VDR.*WKB+6+3 M[;Y*2^_E%9*:5[IM%&4AQ$9PB(EFLC0?)<>HZ'?A7@W8=HY7-_\`$N-C"E'Y M=^#3K3;KM?K73P:I?GIEVH=`X/CG_OOEY7%K'PL>Y%Z5W:.4=6J:K4]`XZ+G M+4```````````````A1W5T1J?=U3HR7MK;4+457I[?.(;@Q^SL;7'*B%D>28 MI6WK=43*C?)+)F1<$HRE-KP"3.*[6U=G4MVOPC9.`YC M/CM&^_"Q7,,>R&6RR7!&\[&J+&8\VT1F7W&DB]1%*>00,Q?173O677?;/3O8 M>\=0IE MM:BY%;G*H!Z)SV^N^N.V*JWP!.86S\U+$6GQK M'+8K%43(9.'2(ZDPG(?N2&T>+)I)+:2)NU;IY!(/".DTO6M/M+_Z:[J[F[$: M;SS65[KS+<,WY>X]78+5PF>L-WLW7EE45F2UJWW**$Y)IK1R MWR*LJ_><-J"S&C$HS/D_%2TJFKI6@+]]B>A."+[`6N_=5=Q]+]$Q<"+.9MA2TMCD>7YIL_95M50K7),DRFWD7%_E.67+A0*YN1(?D):); MBN4L--I4M1D:CI>K!>##-KZMV-7V%MKW96`9Y5U)F5K989F..Y17UAI0MQ16 M$RCL9T>$9-MJ4?N*3]J3/Z$%&O(*85V-Z](,R7OC3*329DHE;0PA)I-/U(^; MPN#+^0HWX!=FMLJZYKX=M43X5K5V,9F97V5;*8G5\^'(03C$J',BN.QY49]M M1*0M"E)4D^2,R$`YH``````````````````````````````````````````` M``````````````````````````````````````````````````````````P` M?/-K:38Z[TIMIA]9L8EE-OAT^(F`XM)-9;$8FQ9;EFA1HBDF51DV32TD3IN< MDKE/!ZO_`),SP[ M#K/(L!UDRFPIGLFHZR.ZC(+RML*R(^=W#QL[*U2MX4\^=N?'X\[EC'6Z#N0BO\`4G&44]ZM[I?8Y))O(^0N M:M<'9R+//Y]FQF\@W"ZL>]P("9C"<7@IH=?I9<:18LL2"(R2@C M%F%:QU*+QX>WC;:*2K=G<24THUE[LYM-T:_1(\O*X;A.-CRN5DNW* M6;==[-JF[;<<:U8;]N3GMA_;VK2E%;DW5T;DT2^PBXC;,A;`7LW]11WU!19' M8UF12IL/'6;'+ZB#-MIU):1S2IO]E8-133%_#0A/Y:O!;+I/J6U^=<98[99Y M)]F5FSR&/CWIPNN4;49Y%N,IRMS5-)S4:6_;27N/;*$_<;-J'&\'P&5E.?#\CUOCG<<(QG+"OV5*VXN-:O=[<)7H5MW-DZ)2HHS MQWTOK>9F2C:5QSA#/L7=EQ24]M%3W)PLW*7+>^&K57*$0 M\UJK*JLC@0'T9#"E%[M1;U1&]$LXOW&3Z"2:U1S1[:R6E?'B:%>IDDS&+9=- MR>.S59LTR+$M;=R">VW*$%';:AMW2 M7ARGNI%R4TFM$P^+X2$L:$K4U=CI#(#ZBQ?7F[N_P#UVQCJ1U'O.D6<];L\1L'L M6G-.PG?%]+[JN,]K\VC(V9'V-78B5&V6/XJX6''7S&'G'S@&O\GW2X(_R MN/X$OPM::`OWVUQRKQ2\^%.CI]/_`/S_``8W9F#)3I@K1%RK7I)/?Y@/\`\Y.S_P!WA_HRN^__`"_ZGH_N M]/\`+]1$?YD#'U\?VJ<8L(6>? MTRTPF6I64SFD$AKSY:5-(SY)/`EU^I!$/Y0LSQKM'V[W_"7N3%]=HZ,Z:KI& MGHESDD&HI6VM+LT>8V*\APW9&?Z*O(U>THG/$CA4C)I@COU=R+K]2=J+FNF];=T?'YV`R#K]LK&STTZ<8N7%.*,G)?CZ@B?T1UK1Y)UQQZSG M?$;-[:/OY%FK2]UL[0K,8;R)+62V#95WZB7'=>9_0I+\0U&?"_;Y+ZB6]?-` M>O/5E-78]K37])4XLY7&PL0R+\X?9"5%]Z:I).6B:5:?7QZF5?A+N*Z'\G<5V2]G7>/P M+-]J_=@IR_TG%[H2A#[IPG)135'1TG2L4>("]PC&\,S.?B.9O9/A=E11G(61 M5=I7-+LX>31YSS3L/F)^6PXPW%(B?%'I0_HWX[L?+]@Z_:YWK\&I2Q_<4UE72+TU3G' MXGD[]Z/*/*W*S:;=K[KBGOEN597%&,8II[4G-4E6+6[$O#,D^3AF? M/F?DHU$:_P#.?)G]W]_U%J9''J=:JJJ4W^/_`,J_9I]/H5`G(%>/JX1_R9FH MS_@B_D_YX'F2XM5KJ>8^,A72/^!DU^.CJMF6Z]Q5N2Y?@SIZIPARNN;ZQR9B MPBU5F\LTS:RCIV&W8JK.PGH(E.^JF8\92C=+E:$+V`^"_B?.[)VFWG MQ'&Y4E"3?W1MP2:WRE_5_3&+>Y:I/3S\L?FOK_P`=]`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`#%MK5XDDC)% M1H_H&VW^U%^+#L_WUTWH#$]L^[JC*=08U78L7]7VDER_RW.F\IO8<6LIKIE- MT=I59'6L3DM3'E-H;4TDW4.+<-)*C;!NFM2=TDO2A"+$]S[FV'C6:8CF?8[+ MZK7&/XIOC,:>]CW.7J5L++UT!OU6`+O[U<.<_3N?CLIBQG_LBM/*1[27Y"33 M4TEK34BK?EZ%[.H_9#>>":)JX&LUXL=ID>V]A0[9ZSHXLF;.AXKJ[!KR.^E] MZ7%B.67D^[[KKOJZ@B+_`!%R<22;U\4$6TM"K(_RJ=K)T+5UJWK_`!2+`G_K M5VQ*II,B5LMJVRRSKX\[&8")I3JZEC1JQ=C M)\^E2=`49V:Z-QMU;TT3VF2.(U4TGR(FTF22^WD3N\:`Y^ M^?CQW-OS7?5J#DO;BW:W=UHSS)M@QMV_[:X^Y89/>6DU]['WG,89G1:6M5C4 M+V&$<$ZE\F"4M/*C!2IX0.3?="NQ^T-#[^T9O[NO=[>K-QXO0T&/6<[5>*X\ M>`2ZR[3;6-I'BTK:4F$6]NF//6HO)MHS=)* MU.+-)$3=I1`M;ISXQ>X'7[!(>LM._(WDN%8+63[>QK:"-I#"+!F'*O+!^SL' M$RK2;,F+-^9(4LR4LR(S]"(O0-R?E`S!:TQ[*\4P'$L;SG,W]B9?2TL.!D6< M2:R)2R,HM&$>,FX>JH',.`N6KU-MO[$_P*05R``````````````````````` M```````````````````````````````````````````````````````````` M````````````````````PR?(U\7]?V(=L-QZ1AUM/N/\1PL@QQ^2W4T>?K:: MXB6*97M+8J\HCFDD.+4DF9[7HX:'4DXK7_Y7^&[7:G+G^NQA;Y_;]]MO;"_] M)5\1N+U?B:\TDJOH+^)GYEY7Q3"UT#Y&N7K_`$#W%[%]1=V]A)O[K>VJ=S'E M6L4GOLR_D4H-P7F>V;UXW=I*W;Q_:6O;[#;U5/*R!RMM4QO)FFB>P;MA^PB2 M95/*B\/I(E,273]Q*VS(EMJ26GO.=/[!P%]8O-8MS'R?;M5Y3.P'3_`)4^.?D;`?*=+Y7&Y#C5D1L*Y;W:W95I#9*,;L9:/2=N/VN, MJ[91;M_C-?>90J:C'H:[55;&1+GE%=9-46*MU+!/N(-PG%H]Q1%PVE:_[C%M MV.,OYKDL6.]Q572FB\5_[59<_,9/'<,KQ]W9Q34XI:*W!O=)N7AR48T M6Y-Z5T9^>/S#^.>F];SN'Z]?_O\`NX5,LI[_!&_.FNEYN*X M(B]$I)*2(BWFX7AL#@..M\9QT-N-#][E)_S2D_64GJ_X*BHCB[VWM?,]UYZ_ MV'G;GN9]Y^BI&$%I"W!>D(+2*\^K;;;<<,[Z&];\^S6;GT[$7Z2_N9S%ADO] M-2VZV!DDA@DD2[&`Y%E,177B\S>=@E$>><<4XM:G/%9>NIR2H6RX)E+N_''U MED2IKTJDR23%L$S8UR[(O,?N\ M?R2ML7,IRMM;=YBYQ54]@N+&NF*]2HZX;:C:)DHZC+@V^/01OD3MB5/8].NO M-KF]AL:;@BG,RM).83)EP619,GW)6>5ME490\4$K?]:D[&!;R$>/L^#7GR@D MF1<1N:5/0;8UJ<.'TST0WJ"YT?;T%IDN`Y#D[.77,.WO9\:=.NHDJ'*KW?SJ M!=(Y&CUYUS"&FF2;1X-$2R49J,YW.M?4;52GH4S+^/[JK)P.GURUKA<+'<9-00<8N[%]N#,@UZ%S:2M89]I MEAIAOV_)"$K-2C.4F%"*./7]'NOM#*U5+Q7'KC%7-..POZ-*KR*SE);KX.42 MLR;J+`[YVX=E0',BFNOK42D2%$OP]TD$E)-S]?4;42[%)4`````````````` M```````````````````````````````````````````````````````````` M`````````````````````````````````````````````````'29#C.-Y=5O M4F5X_29/2R5(5(J,AJH%U5OJ;/R;4]7V4>3$=4V?JDU(/@_H/SY6'B9UEXV; M:MWL=^8SC&<7^L9)I_P/1XKF.7X+-CR/"963A\A!/;=L79VKD:^:3MRC)5]: M/4HR@TEIG%;!FVQ?4>L<;M8ZVW6+.@P'%:>P8<95YM.,S*ZICR6UM+]4FE1& MD_4AY^-UWK^%=5_#P<.U?3TE"S;C)4\4<8IHN'D_D7Y!YO%E@\SSO,Y>%)-2 MMWLW)NP::HTX3NRBTUHTUJBYP]@LT``````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` /`````````````````/_9 ` end GRAPHIC 7 g367209g86i07.jpg GRAPHIC begin 644 g367209g86i07.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`M`+&`P$1``(1`0,1`?_$`,D``0`!!0$!`0$!```` M```````)!08'"`H$`P(+`0$!``$$`P$!``````````````$"!@<(`P4)!`H0 M```&`@$#`@0"!04(#0T```$"`P0%!@`'"!$2"2$3,105"D$B43(C%A=QH3,D MMF&!0B755W7>,%B.\O%9+,*1'R]M7*804[ MG!%XEBM'KLTQ3Z"JFNG4!ZYBO>?//BO9-2O;K:OW8STN-B,[S]>M81< M7%4[J3[HS]QW[1ON"Y(HW+7'LC#QIV]:GF3M8R]/E<;LU<4W7I&4$^CK2AK1 M.>9+138O&P&$#.BN#RLF]0ZEZ"5,[8##U]>WIF M*MS^[_@V*I+;]OW+(N1E1:E:M1DOC5SG)?@G"OQH9?V[[`/)5R4'O6[[-BVY M0K+0[]^<)?ZKBK5N#^#DKE%Z5+01\R4(M\./4^4.OIUV'%_#KZ=0"K>@],LR M]][FUV?_`,[D/_YEO_<%P3_P_MRAWY5BU_X&Y_S);LKY<+.\L\(\@=2-XRHM MP2_>&$DIU*2FY,2KJF6&,FT&3)K&`=N8A2^XU7[3%$P]0'H%H[C]\6?+=L>_ MMVS1M;+&GO6IWE.[*41#N$-@1AC%+U#N M$"C6"@80#\.H=?TYW48U?^!N?\P9F MHWE.XZV1=FSMC*YZZ]W+=C=H9VV7YT3=VVKEJ+;2_O+3D]*K5R<(]$^G:N/>2_9 M3Y8VBUOMFQ@S&O; MG7+C&E[`5E96;D9Z:JM)).L71]I)/\#6+DO#^5<.S/Z?RK;\O;\MUI&_:E;U)- MIN+DJ354^L6U^)?&=^6V,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8!:.P M'CJ/H=V?L7"K5ZQJ-D>,W2!A(LV=-H9ZLW<(G#U(JBJ0#%'\!#"[@X=.'^TO M+'SR'-AJ%4;V^;"X;;E*XS^D+RC:&(9JZ3C)0SET+UT3J3L*`$ MZCW?@/,]"[H@SON7>OF8\:MCHTWO/;/FQ;AJ)[ MN"T(.YE6E3KF.<&34I\BK*0"K](B1Y".CI]HJ5)02E]T$BJ=H=>@4Q7S49)I MGI+0_G+Y!:FHFZ-=OIE3<%TH05'4O/;R,\(^95!XZ8?*#1?,Y"GZBW MWL_6].#2=%GU*[4+*[BHHTH]E[DF^DODT>A!>.D&*13F^)@3*'X9$$FNH+CA MN'?GSGH>)G8[E2[-'S48PEF)EN1$PFL+.2:)/&PJIA5#E(K[*Q>X`,8`'KT$ M?CDUA\!U)%N`&I_(SQLF=Z;'YY;>=;-US%ZG5E:Q%);/>W]=A,UMT[G9MTWC MWL-$ILEW$$U%,J@'-WCT*(`'KE,G%_220AP7-/R=^3G?\_0N.^VY[63)1*;O M56HM,M+;6\/5:3&OV<6T&P7&-0;6*=510FFI71E#.`5A:J1BNI!< M-LY0>5/Q8;EHC3DCM"8VK`VUJ::/5+C>G>QZC;8%B[2;3+2%M,HT++P$VQ(Z M`.](I!16,0RB*R7:"BD9+H"8GR`>4>*U613:2DO%E,D@P3PE3;H(1+*/D^O1DD<[)%0O00 M*FB)#C56"Z4(-S_#GY'>1&TMX6?AQR;E'-YM,!`VI[!6^2+&J6N&E*`_;1UB MKEIDXTY&L\F3WC%3>?MUSK)AU4.4QCC$XTZKL#I7SC)&`,`8`P!@#`&`,`8` MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#` M&`?-99%LBJX<*IH-T$U%EUUE"I(HHI%$ZJJJIQ*1--,A1$QA$```ZCD2E&$7 M.;2BE5M]$DO5E=NWHT8*K1[[;EN8+N!2'>"O=W$;E`I3&U%\@ M_M9%S:^"6X.$6XRRKL6ZM.C]JTZ=/A.=:]U!43?JSX-_P]<6[M]CDWF[( MNJ_=BIPVS%G&.F+58_RLE:GJ=4W:L4TTI*ZVVE"ML+<6UMXV$UHVW?[-?9@W M3VE9V0468L2=3&!&*AT?9B(AN05#=$VR"1`ZCT#US4_DW)]_Y+E/-W_+OY>3 MZ>Y*L8_A&"I""_",4CT-XKP'A/CC:ELO!=KP]LP/568)3G^-RZZW;LNBK*Y. M3=%U*=&-P$P>@``=/A^`?W,L#,N:8T1]F9=HC(T8U`P=>@#\/T]0#TRUO=GR1W#J6Q(QA2@/H'X_A^C\/YL[3%RY55 M3ML7+;ZIGMUQM._Z/N$?>=<3SJ#FHXQQ.D110T9*-UDC).&,Q'@<&\@S73-Z ME4*(E,!3%$#%*(92X%SKD7"-ZM;YQS(G8SK;=4F]%Q-4<+D*Z9Q:]&N]&J-) MGQ\NX5Q?R/L%WC?+<6&3MUU+JTOR M'C#G>+Y'X7BW=NQ<+MOO[=ZV]-R*=%55^:+7[9)/YDTO$KS#XVS?%'D M#.X9ES]VS9E&=B[T7NX]U:[4VJO3*CTR3_=&37RM-YZR_P`QB,`8`P!@#`&` M,`8`P!@#`&`,`8`P!@#`&`,`LC9G_9OL'_H1:_\`F%_DKN#^?QXZ.=M@X";" MNVQJ[J]CM1U>*`TI2\0_L+^N)QB"$ZRG0DB.F$).J.#G49@E[9DR!T-U[NH= M!Y9+40;7\L>6_+ORZOM6:XIW&Q6#K-5GW$S#0U.1F;0[>V:21"N*RD_<)-C$ M,(N+:-GBB2:9T&B!!4.=553L*)"2CZ@W0\Q&E5..GC>X*Z4<&:F>Z]MJ4/*` MP%0S%.95I@41=95!JYIORS\]>)/& MC35-A=!:Q4TO7*M'P%!V-;:+LUPQL$<*[Q1D9U:8RZQ=:U-(B0G!, MPE)^4PY5IBWU!6N)&I.0OEQYC-.3^W[M2DH#74E3G-P9UU]%MW%>KD))G>P. MNH*DJOUYQG'3355[U?G]Y,%%%U%5Q="!#&U%4!9?W!P)#ST0*L(%1'C]KL%1 MZ]H`D,Y?`./4/U0`G7^3$.WZAFP];Y.?<&M*[`-:]IBW*P#:%BF\&J30-#7( MK#HL$$XQ0JRBH**E.R*00,8`$W7J/KD4@"7[QJ7?GMNNG\AH3R(T:6JS90M4 M@J&UF*'!4`)>OV&'MS2]D1^A'$)`J?:R(8Z@@*/N!V_K#E,J+Z22#;9'B;\@ M_#K:\]M;AG)RUL@H*1>N:E9-5V>,:7I&`?+&(UK\Q3Y%ZF]G%037!!PU*B_9 M*)%]U0_3N`E>J+[D%KK^3CDGK^[5RG>1_B;K'D(QJPOF"++=FE8"`V=$M`<% M0E7-3GY:$UZR:VF8J`;*-(Q@BJFLR5*S(0&[QJDIT%,I MTSTIN,NI)"-6XGS>\!8Y.NU:'VZ?6U'#W&<,TBH3<>LVK-^X4*@VC$FA9_L1 M=F>@J+=DJ!6ZA_S]AR&Z5?)+OW(-_/%3Y&]6[RY&CKW<7&+2&L>3EO;V3Z'O M'6&O8*M3=]GB).I2XPMN+\DK8HZ>EF4:J\7XC81ZE7+FHOGKRC*[.7">.WI1A%M9ER#: MJUT_CIT55ZW'%M/I#TDCUS^Q#[75AX]OS;Y$P[<[UZ$9;/8NJ,U&#I+^H2CJ M:4VZPQXSBI1I*\EUML@`9```4`Z`'0```#H`9J+<[GJ!DNK=>Y>T67H`#Z>H M>G^QG49;Z,M_+=70R'%D#J'\@?S_`.UEKYLBULV3TMF2XH@=I?3\0#^?K_?^ M&6=N,GW+3S'U_0RA#(E'L]/Y?_)_MY8>=-U+1SIM59)KQMH&OK/QJY+6"7JC M"0N-+@P6A;&Z!8SN-)*13]9-%B4BY4"%05C04[C$$XG./41*!0#8SQ)QKB&^ M^`O(._[GM]F_R?9\%RL9,]6NW[MFY)*W22BE%VE*KBWJ;3;C1+3WR]RCE6S> M8>';3@9UVUL&Y9-+UB---SV[D$W.L7)N2N.-$Z42HDZMZE.8HA$P'M#U`>G^ MQFE6/N+N7&O@S/-K*E*7=F-IQJ0G?T``Z]1Z=/Q_3EVX-UR+JVZ]*5#%,PF4 M`'T`/3KZ!_<#+QVZ;UHO'!DVR:[PY623-164*:'@YZH3;!,1.8Z;ZP,I MQK(]HF,)2(G2@6_0A0`._N-\3".>EWV6;IE7]FWO:)NN)8OX]V*]5*]"[&?Y M*EJ'1>M7W;/.K[_MHP[.\<;WV"IGY.+E69OI1PL3LRM_FT[TZMU=*+LD339N MZ>>0P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P"R-FB`:WV"(CT`*1;!$1]` M``@7_41')7<'(7]MS]-D>2^^4C_(OP)H"+4!,_R[H"==@09>\"#W]O4!Z=`VI:#OSQ/<<]5;'B&UAI5VT6R MB)1L8C595(BSR3*WDHM=R@[29RT8L!5FK@"&,@L0I@^&0^DJ@YJR#RU5:Y\U:U9:[8(R4K5MXT:KFH&;9.$EF'#"39B8Z8K(+ME M0.7KVB/P'H/7I$.WZADC54^Y!TS6:M6JV;CE?'AJ_7X:$,[+L"I(E=&BHYLP M,X*B:/4,D584.X"B81`!Z=2W7WE6B=X<6JMJVTZTD+3IF[M2V* M5ND/((HJ248:(:F+]&C@>-12>2*:@JE*<2E(/0HCTR*:75DD!W"_F7N_Q0[^ MN]$W%1;9.U=^K(5[8.M%GP0LJ^M4>"!*_;H*3F&+P9(T!!RMI21!D#R4>08WDZGM3ZFTAH^ZPK>B6"V9]];DA=Q#=-`IW53=+E3=@^)?7H.$TY`R'QC^X'K^M=& M5S7NV]'["NEUUY6$JS'6:M6&%586A6",U81S2?5D&C1Q`N&L64Q%URIO3]Z! M.Y,3*'.6'#K^`-=/&+#[4YA>55US"84=:O49G<]D;5M+M,CAS6ZXRM=%C7,DLBF<2G`JBJ;82@/0>@C\!SY< M_*C@X-[.FFX6;4YM?%0BY-?K0[;8=JN[]OF%L=B2A>S9+SKNT3T]9Y!RY>/K),RM@>.WJIEWCES,OW$BLN[7/\`G6- MB8]NQ&,%IA&-J$;:48KHHI1Z)=ET)$N-W&O7$3J%WRRY5NIJ-T,WLK6F4^LU M%$%[[LJX+)/#G:1"3\A(IA#1JC43.5G/<59-NX(02&3[AR'Q7AFS8^PSY[SN M5V'%HWU9M6[2K?R+KKT@I+1&$:?,Y54E&:5&JFJ'ESR[RS.YW;\'^$X8][R; M/#EEY61E/3A;?BIPI*ZX-W)W;BDE;C;HX2G:E)24J&PFG)+QH;VND1K&2TCM MO0KRU2S>,@[TRVF-F;JOUU/ZLUETI5B\C*XSD#CT.JDU,1$W:4#D3$1#LMEG MX,Y=NMOC^9M>X[1=R+BC#(CE>XM3?134XRC;4O5J#47154:F+>?8GW@>-./7 M^98?(]BY/8PK$KE[#GMO\>2@E\TK3MSC-ZU MAUY5V'(:/V^T^GOJ\YOCRJOZ%.5L\DJV=SC)U"LFS]1%=!HL#?W`3.50/SIA M\,M/S-POQGP.-_9-OAOL.5QTRM/(E9EC7+3FU*Y%VXJ3349::T=>\3XO`GDO MS=YG4FG\LF9!B=1<=. M,E(ISOE55+U>]D;0KG[[5BCU&02B(VN5D2D0B_WDG$9!DJE*R;XRACD:K+@@ MD!2J)F,'KU61PWQAXPV3$O\`ES"W'$\[;-LXCLV7_``\C,RH.[]47Z'%FJWJED>*6N`L[15^D@\;1\X M5RN\9RR2+@7`G=C[`(MQ33(!S`.8=Y_>\$;[QB[F<)QMSV3E>/I<<:_)Y-C) MBYJ,XPO*3G"ZHR<]5WY-$'",=4DSM^,[?YXV+D=O"YSE;9OG%\C6I9./!8U_ M'DH.4)3LZ5"=IN.BEKY]58/]VW6O\`89)ASSI9:\V^.X_ZV9=_VV.:^ZMU9=]QR:K"K,T2 MQ\-?#O+/)& MZRQ>/6(+$LP]S(R;TE:QL>U%_-/\`"65O M=R7\J]-0LV+47T:K4^JK8^_ATG%S#:"TV[M,\WBDC-[ M#<9Z0:FB;!*IE*FL>IQ"4>V=,X,JQ#'36>[?(6!XNVO=+6T M>,9[AF6,>.G)SHTI1MQ48M-U;>F.I,NL40'U_#^;.AVZ MV]:,WX,'W)M/#E6W[6K;OMJJ:I(ZU/(A MW]`*)P,4!$2FZ>EWV7;5D8^R[WNTTUCW[^/;C7U=J%R4FO5JEV/7M6J79GG1 M]_N[XM_>N.;%!IYF-BY5V:76D;\[48J7HI5LR=.]*-T31-'F[9YYC`&`,`8` MP!@#`&`,`8`P!@#`&`,`8`P!@#`/FJDDNDH@NFFLBLF=)9%4A5$E4E"B11-1 M,X"0Z9R"("`@("`]!P"SZSK?7=*=.'U-H5+J3UVW!HZ>5FK0<"ZF`6U9J93[HV;L[C5*U;&;-<7+1K9H*+GFS5 MR8@I"X;H2C5TD@N*9A*)R@!NT>G7I@%4B(>)@(UG#047'0D/'(@WCXJ(9-HV M-8MRB(E09L6:2+5JB43"(%(4I0Z_#`*!9M>4"Z.&CNXT:GVQU'I*(,'-FK,+ M/.&2*IRJJHM%I1DZ4;)**$*8Q2"4#&`!'U#`*7*:AU-.*-%9K5^NY=5@P;Q3 M%64I5:D%&48T$XM(YH=W&*F;L&HJF]M$@@F3N'H`=1P"F?P&T;_F9U1_W=U# M_(^35@N&N:TUS3GBDA4:!2:L_52,@J^KE5@H-XJ@80$R*CF,8-5CI&$H")1, M(#TR`>6ZZHUALA-1+8&NZ3=049'CA4M%8AIMP1B<5#&:HNI!FNY;H]RQC`!# MEZ&,(AT$>N`4NB:-TUK!0BVO-6T&F.4S+F3>UZJPT8_3^92!!P4D@W:$>D36 M1#M,4%`*)1$.GJ.35@RF8I3%$I@`Q3`)3%,`"4Q1#H("`^@@(9`,`3G%+C-9 M)%*5F]":ED)!'L['*M#KA#=4UC."G.1%@FFHI[QQ$3&*)C?`1$.F35@S+`5J MN5..)#U:`A*U$IJJ+$BX"*8PT<19;H*JI&4<@V;%55$H=Q@+U-T]<@%;P!@# M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,` M8`P!@#`&`,`8`P"S-CP#JUZ\OE78]HO;)3+1`,P.H5$@NIB#?1S?O6.!B)%] MUP'4P@(%#U'.OW;&GF[5DX=K^\O8]R"].LH.*Z^G5EP\2W.SLG*]LWG)K_'Q M-PQKTJ*KTVKT+DJ)=7TB^B[G\\GY12.75CEN@*L%EX];H(&#W62AVJG0P=`, M'N(CZAZ#GE; M;?C#JNB-3-(DVV^/&P&,Y,4[YALT?VJN-2VQ!G+1'S#SO>/WB5E3^:67%%,' M29PZ@"B0'V.P<;)\E>%K/%]AC;>_[3EQG*S5*5VVO=2E&KZR:N+4WI6I/XQK MYC\IS-O^W7[R,WR7SB=]<%Y7M4[-K*TRE#&OR_C.5J[IA2$(O'E[<8:Y>W*+ MZN,],?W&CC/MS;>WZA3650M->$9F.>2$M.5^>A63%BPD6QGK@'SR*!L8S=(I ME!+U_,F0W3\,P;Q/@?(.2?R#)S\+*2Q[D+=JS?LW9SG.W+1'1"YJ^9TBGZ2:J;H>4;?VOMV\A MHIGKY8LM'ZOKDC1IR?3]HT=-SJ=B>KO21CA`1!_&,"$`A'!5#)JBH;LZ``B/ M?_8=!U]0M M\31].;QUK`(U^(V"BZB64'8X=N3Y5%L525529G^<.1%8[%0I3I.A,+=7M.S3>,\=;_`.-]WRG?NX+C=G>L79/4Y4M)S6A.<%>BVI6Z*["L M4S6;D7Q#V9QA5CY29>1ENH4TY!M!7FO@8O`O*/%CAG9L[6;QW(GIM95FNAMIRC&<6VX2E%-KK*#_;.1 MF3Q-YXX?YEA=PMNMWL#D^-#5>P[]'-)-1E*W-)*Y",FD^D9K]UN)L_PQDXXG M%_F*M-HR:\$1"B(V`L.BT=2*<`Y1FT9EPW2>R$6@/RT:=10P^\4Q2%$2@8P` M4<@>`+>%8\*>0UN4+T]JG#"C?5J,97%8DKRO2BIW+4?EMN4F]::2;BI22B\- M_<)B9=CW5>660D[?8EV:02RNP5&_1,YVJ"Y4VK0JAFJ1.\ MO;WE-V_%]P^V[IQ/CFR[+P25O'\/[CAQOP>.W&[EY$H+W9;@X]'IC)1M6E)V MHQU*FI.E/V^?TOEG(=YW+FL)WO+.W9Q7@CB+X; MXSV_!O:?YN1;_D7=-::KU)1571_+#2GZ:JTZ'B']R_.ES[S!NFX6-?\`3L2Y M_$LJ5$]%BL92HFTM5S6UUKITZNM3<',PF!!@#`&`,`8`P!@#`&`,`8`P!@#` M&`,`8`P!@%G[#3SG#;K+0])\N=O!8*=4FUPFANO(+8M?9&B5Y1K#$^4 M9Z5W1!M!OW6OFBX$T1/?-^Y1VJ3J;"&#;?)91\]HFV8[4&RXIS9Z<\<5]Z6VT5RX@EK?`*QS@'%?7DUVGS)4T M5?V!SB!.TO0I:*4E3\22"_B/K/RQ\V*=.7;27,#9!HNLRB,/-H7/D5LNN/$' MKD'1VORI&J,TF\1529G,)NY/L'H'0?PK>F/=$&X$9XY/.2WE(MP\Y;RJK-O* M1SAZD/*O:2H*LD'J"KM(4C5\"J@JW(8O:/H;KT'T'(U0^`++\XO++D[I3F06 MGZDWUM+6]7#1=(FAK].MLE"Q0S#R4NB3R3^4:JD3^<:^NIG:.EN7.PRU>"M[^D/@N7) M/9,!*?6XZ+AY=R*+)HUF"'8_*3B':H*A1,?N#M_+U&MN*]"#>O4'CZ\TU9VW MJRR7WE3*3%%KVQZ/.76(/R>V9+DE:C$V:,?V2--$NX)-I*%?0S=9(6RIBIK@ M?L,(%,(Y&J'P!TUWBWPNOJ7;K[9')65>I59G;9.NS%4,5K#UV+=2\DX$J*:R MI@29M#FZ%(8P]/0!'TSC)/Y^=R\B?-^T;+LN\8W?.[ZW5IW9,C88NL1=]MK/ M7T0T<2RLBQIK6';OPB"QK.)*1NJ@DF`"'40`IC%SGHNQ!WE\<]SP?(C1>JMV MUT40C-DTN&LORR*A%`C9%TW!.;AE1(NY!-U"32+AHLF*AS)JH&*81$!SA:HZ M$G,[Y..;W+_:7.AQP>XT[%F-/Q=;FJ=26RE>L;:AR]UOMGBX2PC(S-Y*\0?1 M]?9ISC9!%!%=N3M26.JFJ(E#.2*5*L@P[R2T1YB.$-#'D'9>66R+-4:C(PA9 MEQ$[FMMT3B',J[08-5YJKV5N:*?P9I%P1`QUDETS'4(!R%[@ZDXOH"4BANP!RBB4J>A)S<<,*7Y7N=%9N-DTARZV:##7TK"P%B_??D;LFO.C M2,S$FE6IF*31&:!TA\L0>\YC)B!QZ``^HA6W%=T0;R0?CG\XK.9BG4CRUE5X M]O(-5GJ`\J=HK@JU36*99,45(`"*]Y`$.T1Z#D:H_`'536VLBQKL`REUQC.,5M>;X0FDI>]"TE"]&GU6[T8U4],?[2-R"7R5>V?B M\U(UMM$W5L#2]JC4^75<8QL+KZ$LS]M'Q,#$2SA9U*6.,C%%0"R2AV4;V(JN MBG9,UP`#D_-WA=_AO8(YVV[ENG';\%SZS&,+$+DE&,(R;9SF[L?)>.\6\A85Y^"O8M(R7:5V4UZRG/NR/ M*TZ>VGJVPPU9VC1+3K>1FE2$C0M\(^B473<7!6RCMJHX2(FZ02,8#&`AA.4H M@(@'4.NO>]\2W[8LRW@[[B7\*]=?R^]"4$U6FI-JC2]:=?\`.;5[)SWA?,]K MR-WX9N>%N^'CQ;N?Q;T+KC+2Y*,E%MQD^RJJ-UHW1FRCWA-RPB%6J;?1]WL[ M%\P9RL?,U&.)981VPD$BN&*[>5B5G3!0ZS4Y%!(10XI@<"GZ'`Q0^O<_"ODN MQ3 M:NSMSM95QX]Z,X/3.,K=U1FDI)QJXI2I6-8M-R.:ZD+UHC@]O.L\LD7T2PMD M>W@M(:\O21U+0K85&4DBL2,C7JAY!NSBG81[H%B`1NQ(GW%-WCT',^RK>N$^ M#=_V?RM&<,7,M*UMN)DIN][SA-/1"59J-N7M7%))1M*-4]71ZE\KQ>->2ON/ MXUO'@^5J_DX-V5[>,[#:6.K"G;:=RY!*$IW8^_;TNL[SE1K2JJV>%\7(.^%7 M.1\04SIRM2:),Q`XF-[L57K/\V54I0$2&`#E$`^(@(#^.6CX4V+(_P"A7D"E M-.5A1C'XUMV;ZE7_`#JGX,[K[A\<^3[,LWQUEJ3MUC[DL*[-:7W#.M0>I6[O[)S3C%15Q*,X_ M).2I%K%O*#C-:M%RZ,W7G"FP],V@@R="V9`$"3BWD8N/N)QLXO'@JWCYMBF< M"FZB5)P'0Z?01,F2WO(_A?<>`[@LO;)?U'A65\^)FVEKA*V^JA=<*QA=@G1] MHS^J/K&-Y^&_,>R>2=OEM^[16U>0<)^WF[?>_L[D+BZ.Y9C.DKEF;3:[RMOY M9UZ2E]^"7'=_R.W?"-I&/B`%3 M*J8A!.A!'+G\#^,[O/.:6+>1;D]BQ&KV1*BTN,9*ENK:J[C^7HI-+5)JB M.#[EO*^/XF\@`&>KT(1MP4()*$4DDNB279 M+\$>'4YSNS=RXW*Y)MMOJVWU;;]6WW/IE12,`8`P!@#`&`,`8`P!@#`&`,`8 M`P!@#`&`,`LC9G_9OL'_`*$6O_F%_DKN#@1\:6\>6^@;YLVY\0]216W;0IJY M!K?(R6K,]:DH*FM[`P>HRS>,K=AK\J=TO,HI-R@F+D3BIV@G_A!RR2?<@S)O M?FSS-\D5PK/%O<$YJ[3[<]YAVO[A.XQUJV.+=VRCB-;MK'(769?2*TN1L#,]N3/3:G:U6TTU1>ILN]6Q,':K$%DCKB!$S`!^G<(?#*Y::]2"5 M?4&Q_/<[VUJ]IL^):DUJZV'36^PCEU5KAB)*0M88].TF!ZTB".V8EA#+C[J1 M@43_`%BB`@&4_(21I_<+?_7:'_AYH'_/-]RJ';]2&=HFJ_\`LOUO_P!`J?\` MV>CLXWW)(ZO-7_JU^1/_`*.M?_BQ1\F'U`YOO'7;O*M7-*V)MP99MGFJ7&Q9 MAS8#*4*HV8Z5\&$KJ4DB,C8XURZ)_B1*//[29Q2*!P'T,8V5RTUZ]R"7+B]L M'SAR?(;4_,J)9.,BD9!D/SI4?SI'*?\` M#KT$BG3N29L\\O(M'3O"YYK".='2MO(F?;45DFD41.E4(55I8+T]$X``I M]S%%NR)VF*I[CXI@[BD.&(+K4,A5UI0N)0>)G:FOK+OC24;R=N$\?;UU[ZI5%7B)%!)^<"5-O5^!!)-]NYR+; M6K2^S.-DLZZ3^K[`2^5LCIRJJ[?5"Z*"UD4&Y%G2_1M6IQ@0I@3(BDF201*` M'-WFR)KU"*#Y5O$IL[D/O"1Y(<8):LR-TL#*";7?7[B?:UN94FZZU3BT;3$2 MCMX1JH[&-:H%73%1NJ0&I?:(J]?E=C4Y6/8R)/D$G,T[D57<*B\4,4K,4WS=/'DCL*(J3+7MMKFJ-Q5V^T=BZ2>,XV4'7$ZX82T8Y(W9KN8:;9@/L'6 M235!5NLF/<"95#TZ=,E\*DG-'XSK+Y*J_3=B*\"VJ3JOFF(!ML0AJ=6+.0LZ M:),XASJ_O"Q=`FO]-$P%,F/4$_RCT#H&52T^I!+=KC9/G[,BUAJQ.-R&1-+3;E]*4I4;4)U49::>CZTH M]FOM-\G\T\9>6\;+X=M^5O$\ZU.Q?V^Q*6O(M4]QRMVU)0G>LJ#G;UII+6EI MZ M/"O,7BGRUA>ULN=B7<[JKVWYBA:S+$X?WD+^)>^>$K3Z3>EP3I2;JCYPN_\` ME)#,HZ-C=R\@HR-;I)H1<>RO^QFC))NF<4TT6;5*5(BF@0Y1*!2@!?00SKER M?G&/:A;Q]QW:%A*D8QOY"22Z424J)?Z"=Q\7^&-PR+V9E\?XM>RYRYULH"AYEY7FC%5-+Z@_(5-95<$D3J%!,"Y+Y1O_`"/%5;>P6MGS(;XL6 MXY8EB_-6EAV9*BM0ORFI2]BRVX1AKN1@]6K0*G;NVU2F9V-,VKLBI,C@F"C* MMWFS0C0P)"<4BBWC91LCT2%4W:';T+W#T^.8$Q.01AX]Z76E?FN6Y/K15Z]:+X'G ME+K8K/(K2]IL$Y9)9RH=5Q)V"7D)E^NJJ("JJH\D7#EXW[V1E2;;G=G*Y)M]VY3;=7ZNISX7'=JV;$C@;+BXV)@P24;=BU M"U!)=DHVXQ22].G3T/LUL#ENFJBW>O&R"_\`3H-W;A!!?T[>BZ*2A4U0[?3\ MP#Z>F=3[.3;BX6YS4)=TI-)_FDTG^IQ7]JL79JY38XUMMR_/^3>C&%E3N M>VYR?1N$:KOU;TNBJWZEO\A_^K<4V[*YOOUK%M0P<>5RYD2MVE=5N"JTKDM, MGTZ*.M:G2*ZM'4QJ[6M$\>'%FZV62*C+/:]!JW2\OHX'91G[(FP;,V<%&+OU M7+E.-4F%0;,S*`0"?,"H8A1$V>IWBOQO@>-N.1VC&T3S[TEB+KH3IT;=$VSPH\[>9-T\S\RER#+4[>T8\96L2S+36%G6VI34(J/NS6GW& MJ]8I*321A#4U1HVJW#_&=.I7\-X^Z+#7CF.1D^/)2'NOT` M?)I@H4ZRJIE0/W@DD3M(.3GHBZ=6836MJO8R6AL_DKK_`'=PVT[M*WU.8D=E M([Q-LUQ6H)@1E8T*E`HRM-<-G"T8Q<0[QJ*W5P5HFBDH(``@8.HC%(M-H5:: M3,L7SG7QNUG<9:CW2US\/,0=C9U.5S\PHF1$ZP&(4PF*8`:)=B- M2I4Q+M_R$4(>/.VMF<>7Q+G===E@6[N"L==L$&K726&4:QZ5CG(.:;P4DX@F M2:XF.HD8"%.9/O,!3!W2H.J4NS(@"2BBK9,1(!C%3$!(.):5THZB.KO7H7 MX'DEXC@JN5:^3S5HTL2]5>2SO7E\;PK2<;**)K-',HI7P:)%)[1C>X)O;$H= M0'(T2)UQ+JHW/+C+L6X5:C5J[2AIV[N5V=1&6I=O@HNP.45%T02C9>7A6<3J[X'1$TV#*M,Y<5FZ:3ENU7.;VVX@4!Z5::M>BH4ZJ+XNI M[MG>1!]#W7B;886QNH355O;)?74@:15E(:+A5'K6":2<8YLA6;:3ERD M258BH"I1]#G[1'"A6OQ#GU5.QMNKS.U9L.D[O;:AL\HCLK6>J[/>0A;12K'6 MI)B1C$/%(Z6"*MT-'$D6;>2*B"A0*Q5J3[=S076W/_?\` MO*B:6TKIX\1+\E+I'ED]C[6EZZV_C:OVUL.?LFQ9:EQUE:OHW7MA=.K-%NWKR/;R?R5;C)!DR7469'**(J>Z! M2=Y_4W4:%%RZKL5:DNC[EUU3E]Q[N>KKAN.&V`U)0Z"Y696Z0E8Z6AI&$?II MH'28.H&39-ILSU^9R1-JD1`QW2QO;2`YP$H'%IT]1J35?0\.J^96@-R71MKV MEVJ4&XOH8T_'0=@J5HJ[J3B2-B/3NHXT]$L$7@%9G]T2D,)P3`1$/0<.+2KZ M$J2?1&TF4DC`&`,`LC9H@&M]@B(]`"D6P1$?0``(%_U$1R5W!R)?;9.6R_)K M?947""Q@X_19A*DJFH(!_$&"#J($,(@'7.2?8A&W_GUX.P;^G-^;M!0^E6JG MKQ$#MM@P8&%O/U]TZ(VA+JN=DQ.9M+UMZ*:#ERY4*BHS4)W"!TB=T0EZ`\&H M^;'%.-R:N? MX227'5@Q"JV23G4I4ERV8PG0,A1TR0([. M!_E\O?`O4M@U)3=4:ZV#'6"^RE^7F[+;YJ&D$'-3:Q;1VU.U02@"* M%.(@<3*F`?0"Y4XU=0;]5/[C_D034?_KQ\"^O7Z[R'_P"\FO?^ MX.4ZV30A/IKN%\2OEW)4G%D<1&FHRT,(&1F[D^.';H_9L>T6+8YMT6-;_5EZ M@BL94[EJT`5G<,@8EVQ;H-591,HI@N85E MD$Q'VP]P2G*4*.H)0?&EQ6MW';Q>I(+,I>42?.7!D.P`2:G0ZB)Q/TANLE^`(&O'GY3KEX^Z?L<K6 MM"V,ALRX?`=LX)_QU)3N$?<*H4-(O(&!S'Q'O3M\;W#*L\8RW*=F,9RE"WUK*U*$ M]23BW6,E]:=>Z:/<'[?-_P##7W>\+CD>2N/[9F^3]IC;LYMR[8MPO7_DI#)M MW;/MSG"<84N0?]U*-$M#BWK,^\G?-F39O6O\8&\2^D6S!H_L=>H&OH"WO6\8 M':S*ZM<96D)MP9(.OJ=8W7N-_OARR\CS%Y&NVY16>KU;L; M:F_U?Q,P8_V#^GU_EZ?[N=1*VGW.:Y8_S%90 MD3``>O7^_P#A_/GRW,=,^"YBQ?;H5$DD`_[O3/EEBH^66(T?4)`3F323*HJL MLHF@@@B!UEW"ZQP31;MT4P%19PNH8"D(4!,:@UVGL<"K M;:NT0V=)PY"*IH42$D6Q5B1"_ND26L(KZG+Q+^[S[D8^5=]GPKB=8\&V MZ_*+NMIRS;UN5'=5&U''4E6TDZW%2Y-_1&&ZO*C5KW=7'C;.L8MP#:5M%3MY`R2"15!7(0AW"9SE$" MB!0KE!MUCU3*%-4H^YKUI':FQK)-\`MA[(LLI:-A.'/-5*#D;FN*DC./DZPD MA1(0O:#=5\20>G;M6B20>XL*I2)B)C!E4DNM.W0A-U3??J:M[&Y)W';O'3:3 MK6NDI%)QK).&AX0S=4"$(?YGYQJ10Y M>PXG"I))JBZ?$I;;75]3,V^:H_Y@S5+IFL8R*4E>+_$&FV*_6M4'9GUHG`I] MTG6%\O7XLEK5V]$7YKW?^K87=G$/D M[:(:'JVF'>D7VGGDBD128@M47VA+V./?,UG`?4%XY1[]<:N4RJ#]0.V[JU9/2?W* M"%W:W=?<&^2/#%1CA.Z,)1$B)$%%"^\L)0--14?W5%55R_:859.M()\\./[_ M`('N[:G1I:ZU36-((NB?())"F9$ M""4P@ZZ'K[CIJ6GL70A'0ROB5Y(2ZC9FH[;[RNL@C(&$IE4'[+>,#$M'*2_? M^R6:QZID"=!`"D,(`'KA?WB_(/\`NW_EZFZ'*:(A(F^>,E-@P8L"L-[5F&C" MHD(E\M&!2`,6/;>O7V.K)(>WU'JF`Y3']WY%4NZ_,T9UFBZ>>-;F&M&,7$NM M&\C+%*K-XY(7+@C.(F]>R,BL/M@<4DFK-L=14X]"IIE$QN@`.2_K7Y%/['^9 MD>R[2UENO?/C!E*+8(JU0L>L\JD\1M[X),[3`5>N.Y.#=$<(M1<.HMV*)CB4 M#I&,`"`F#"3BI(EM-Q,L\CDV;?F?N)V>SP7UA-X9!Q#-VR;./*#1PHJ@)'J_8'F?)7I8THT;/EH/ABI8(@C@I%/E)1*Y/8M&133.`] M54&DJN4ANGY#'`P?F*40XU]#_,K_`'_H:*;MH\E8:GY/6=-([0/4^3VH;>\B MX!NY6<.V+6$!:23!!CU.G\N[E1D1,$JGR&O8IC'='=1L@A@%JLM:ZZC6[UI'4"E,&DDU692+9E58)JW?L MG/M_,-'J*#`B;IJO[).]-0#$-VAU`>@8!3/X-ZA_S5:W_P"H]8_R7DU8/]+I MW49#%.35FN"G(8IR&+2*R4Q3%$#%,4P1@"4Q3!U`0]0'(JP5>35@J;;6VNF4;)0S.@TII$3)FII>*;5:"0C94S%0561I)BDP(U M?&9JB)DA5*;VS#U+T'(!3/X-ZA_S5:W_`.H]8_R7DU8/VGJ#4J)RJI:NUTDH M0>XBB=)K1#D'X=2G+&`8H]!_#(JP51OKK7S283L+6BTYM/HK?,)3C>L0B,PD MN"/R_O)R:;$KTBWL#V=P'`>STZ]/3%07C@%G3FNM?6=\,G9*+3K#)&13;FD) MRL0DL^,W1[O90%V_8N%Q12[Q[2]W:7J/0/7`*S*UZ`G8WZ--PP[3R+!EMV\687L6 M7H^Z?:L7W3_R=47APCGO+/'.^V^1\.S;N%NL.FJ#Z3C5-PG'M*+IV?5=TT^I MR:\VO%=N'C7*2MPUI'S&UM+*.%W:$O$L1=6BF-3]%OD[;#QZ0F!@RZF*621+ M\L9,I15!(YNT=(?(GA??N)7IY^T0N9W'FVU**KG&RY+IJQKLW]<^C>/-^XI-Z'.*JHK?< M.FU-[T_'IG#*R_0^6>-4ROJK5>SMUVAE3M7T M^O^^@0CJ8.[ZIG?]@"1,@%0[0,H=3>7Q9X3VKA2CO&\QMY/)'!4JE*%BJ3 MDK=5UG7H[E.B5(TJW+Q5^Y;[O^1>7YW.)\1E>V[Q_"]*J3=N]FI2:MROZ95C M:4:25FO63#2@8!;$E2:9,NU)"7J58E7ZH$*J]DH&*?.U2ID!- M,%'+IHJL<$TR@4O4P]`#H&*L41Z2U6KD&,,2MP)#0JAUH<2P\>48E90Q#**Q M@@W`6"AS)E$3)=@B)0Z_`,58/@YIE/>/'<@[JE:=/WZ:J+Y\Y@HM=X]271^6 M62=N56IEG*:S?]F8IS"!B?E'T],5%$>Z/KT!$JN7$5!Q$8N\(BD[6CXUDR5= M)MTP203BP^5^5%V)/R^YV=_3TZX%$>I*LUQ"+7@T:_"(PCD3"YATHI@G%N!.) M!.*\>1`&BHG%,O7N(/7M#]`8`B*S6Z^*IH&OPD(9<.U88B)81HK!U`>BHLVZ M(J!U*'QZ_#`/\"L5L(MQ!A7H,(5VJ==U#A$L`BW*ZBY72BSB/^7^4654,=$(*9',>=5(YF:Y4Q M[0.GVF`OIUZ8!YVMZ+%)Y[?S" M;,5?S>T!@)W>O3K@'Y1AH=LI)*MXJ-;JS)_Z[3+32QN3O9,8:8:(1MS5Z%VW M;BNJM0N*VY4DXMI$>CGP"TXSI=1CR=MS5H94XMF[C6L$\<(H";JFDLZ):&9' M"A"^@G!),##Z]H?#,5W/MAV^4VX;Q?5NO1/'@VE^+]Q5_.B_(VIL_P"*!OZL MQCD\-P9WU%:I1W"]"+?JU%XTW%/T3E*GQ9?.O/!'IJOSB*K[(B2:;ERU:-RRDJ9(5#)N)J4*D5[+NB^ MX/11B^6"2_`R/G;EI#`&`,`8`P!@#`&`,`8`P! M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&` M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`& M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8` MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#` M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8 M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@# M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,` M8!BG>>Z=?<J(- M43&!-(ICF$.@!UP#7/@IY%.*GD?U_;MG<3KS(WNGT>V%I5CD)*LS=759V$T6 MTF2M"-)QJU<+D&/?)G]PH"7\W3KUP#%EG\O7!:G\XH;QUSNS9AKRJGI^`K,; M2"4JRKQBLQ9J^6SQ#8]G28FA$@<0YRJ"8RH%()@*(]<`_6RO+QP7U+S5JOC[ MO&S9B-Y07.8I<%`4M&E65[&NI/8#0CVL-U+*V8GA6_SK=4HF,=4`3$P`;I@& MQ/,KFAQ^X$:1D>0W)FUO:9JR*L%?K#V<804I8G"X-5[R,2FSI=#BE:)Q&N0UY+2[(I).)=>TR=-3;&K! M&(S:(#/Q"Z/<9("]"@;KT$,`K_`ORI\*/)6&R`XC;1UFU@?4R.BZM/VMZ^85A2-0EGSEO`LW9V#1-Q*I)IG5[05/W`7KVFZ`;` M\0.8.B.=.CJ_R*XWVAY<-56>3G8B(G'\))5]RN_K;GQS\4.437AY MO;=#ZD[OL+/[0TCU89FT73?I&65.H!&Y3=R@E`! M$`-N.97-?CUP)T>\Y$\EK<[I^J6-@KM87GHR#E+*L$O:5U6\*BG'PJ#IVHDZ M41-^T`HD*`=1'`,A\(8GND(8G>40Z]0$,`T%V_=:9L+[Q[2ELH%NJ]YJTENS3(1UEIT_$V> MOOQ;:/0;.2LYF$=OHYR9NX2,FH!%#"0Y1*/00$,`NKR&?_V'<9/]*G$;^R\? M@$^OWY/_`.+;1/\`I?B/_N2V)@&$_MFIR6X*>6/5 M6F+%)K)4KGYPMJMRK*ST0(C(R-@KZ.SJB1L7H5-9RTDJU+1Q3!^//AI-3DZJW$#H1DC5XMM=K,W5_723/(VR^1S` MP_K=P``B`@``!U9?:C_ZE_0_^D#=']OI+`.3#S%Z^M?EL\Z7-W65#DGJT7Q` MXP[+)#_)?UM$ZO&;6;NT3,,3T411^O[6G7#(PE_,(J!Z]0]`.E3[/?D;_%[Q M;R.H)!^=W/<9MV7&E^TLIWK(U*[D;;!K!@#KU*U([F9%LEZ>@-1#\,`Y+ONF MJG:+IYN-XP]/A9*?F4=1:AF0CXA`[E\$=`ZL:2\L]212_:G3C8UFJNH)0$2I MIF-^&`2@\R_((7R"?:?UVS6:9+*;GT;O+0FB-S`LN161=SU+?+(UJUO2`(J` M-QIYV;HZAO51X#C]&`=8'V_O^IK\?W^@J/\`[03V`3$X`P!@#`&`,`8`P!@# M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,` M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@ M$9/F@_U3?D0_\).Z?[&R.`<#OV^W@!XN^6KC7N'X MFZFLUQM]%UQO'6R\3/7U6(7L[L]GU2O9'I'ZL%&Q$:H5N\DSD2$C=,?;*'4. MO4<`W0\B`@G]X9QC,H/84=J<1!`3>@"!JQ'E*/K^DWI@$^OW6C`*`CT[A_>1V/0/TCT`1_D#`(%=R`(?9;:(Z@(==O1`AU].H#R2V)T'^0 M<`UVYNH2O$/C+]LUY3ZJT/\`-ZLU1KC7ES%@0B3V784"P$V1#Q`J@8@J*3%5 ME;(RZG'T(8`Z]`Z`!3.%\++\G>!'W+/E$M[=P:8W76;'0:HJ_*0[N-CK;?6N MU+1$IJ@)NBO4<`XPO$+YF>/W!3E7S9Y4[I*VN\_5%+7*1XG5EB+M6Y`2]POMHF`P=!#`)//LZ.3=< M@/(#S$X]5@DG"ZWW]0Y39.MJS**HB]CE=8W-RXA&D@1J=1D,DSH=Q727,B(D M$Z/Y1$O0<`S;RUAXJQ_>3::KD]'-)>!L,;K.!G(A^B1RPE8:8X\3D=)QKYNH M`IN&;YDY.DH0P"!B&$!P#G(\G>K-K>*OD1S[\:L>,AYAY!/3"4HJF14Z^A"8!_3!^W]_U-?C^_P!!4?\` MV@GL`F)P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,` M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@ M#`&`,`8`P!@#`&`,`8`P!@#`-&/)OIS8?(;Q[6NNVNN+A=-[)7.MQK6TURU%?UT*3!1!GIW5;D))JU,$BS5)[9S@<0+W=.@X M!H]NKQ*<[K=]S-KOR&0.H63SBE`[2U;8I+8@WBGH.4(:NZG;UF8=_NPO,)V, MYVLRF9($RMC&.'0Q>H#U`"_?N"?!7RJY61WQWV>.:4">CR8^(/:?_`.!>@>,GA;7QVU>=82>FT&@RLQ`U!:UJUZR/ M+%?[H@8OYA^(?D=R+^W-XT\)6^OHT> M8?'BEZ:FH6D+V2N@DCHP]NHRU%VI'Q=%3?13 ME)HQ?E++$2:-!(L)NTH"/7`,D;T\6O-JY?\4*NMK@9O8AKI4 MV[EJE`ZDD:O*G+5UI0MC7.VG%RI=I6P]Y1[P$0P"M?<^>$OJ98KN9B9/ZK.NHY@N_I=C3.0B9UO<.VDS]@=$N MF`3>>(+0&T^+/C5X@\?=VUY*J;5U9JIK6;K7D92.FDHN71F)=T9N23B7#J.> M!\NZ(;N24.7UZ=?3`)(\`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@# M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,` M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P"S=B7ZK:JH-UV;>)-.%IFOJK M/W.U2RH=Q(ZOUJ+=3$L\$O4!.*#%HHX!P[/_NCO);R+?;GVWX_ M_&4CLSB;HM\^6M5\L4??+1.-:['H*R`R5L>55[%1$`^S].S4HK)1,;>:7KR3O4%\A M.MDFCV1I-P;,BF07]M)RD`+(F#W$1,8#GJX]?=!>9#EC7IZU\:_%%2-WURK3 M"->L6?@^<_O,BG)P\V=V3HH`& M4(`=0*(X!XO`_P"6NV M-PM?%-XWC;WT1I1^X^L7:>A[I:K1*P:*KPC.=EV58DX:(K06!O'*.6<:D=Y( M%0'\PF,`@`$TOA6\X57\L>H]Q&F]8AICDEQY105VCK(DDZDZ\]CY%&3"'LU8 M>/DF\RWC59.(<,G;-X3YEFX2`!.H50I@`AK\?'W7NZN4GD1U!P\W3QTTQKS7 MNU=I6'4R=^J4]=%IZ.L/9,LZ68$)M^M%K$E[$S:,E@$H"`NNXO3H`8!+QY_/ M-+:/#[K+0U M3*8P)@"QS#U$H`(&)N+/G*W7OSPC4]T$52AU3+V]O4>@$46C?N5_-IR8H2&TN/_B&K.W]= M.963@V]RH<;N.?KZTQ#&1)*QR<@SD3HF=L#N"`J3KU*)@P#L:X1;#78>X>5Y;2EK&]-/G!+RLB/&#GYIRV5#:#]4ZQ8>/: M+7&9US>6$B)2$;F4HD\QA[&AW=51;BH0G4.X<`EI^VTMCKRS M-'^OMJW;H>>GXL_O)]#IMFMTIS4!$P]H'<`'Q-@$^/E!V5">6/RXU"/@3-I_ M3/$GQ:[*Y'R+5LH1_#-)Z;X\6/<[I!RN(G0(^;6&SU]@J!N@@O'@0?4IN@%U M^.`1_P#U`_(C\.OU#?@CUZ_B\UYU^'X]/A_=P#4_P>^8OG[PPXBT;CIQ^\;5 MFY):A=;HMDNKNN/8[.<,B.[?,PB=@CR'K%:DX+W*V0G4_P#6`Z=0[P+ZC@'] M,2'=KOXJ.?.D?EW#Q@S=.&W00^77<-TUED.AOV@>RH<2_F`#>GJ&`5+`&`,` M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@ M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`, M`8`P!@#`&`,`U2YQZ2E.27#WE!H"$730FMR:'V=KN$474]M$LS:*G)Q<:10Y M.JB9%'JZ93&#X`;^Y@'\Y'QQ^5FL>(OB[R)\/U96I2)=0TG+5JF:MVO)2EBC8-XD5VE$/YFW%91XF3 M+[H,CB4!*8HB!%3X#O.51O$)H?=VI]E\7=Z;9_,J.EG$=W]Z8B00]/3IZ@=(?D&\A$#Y3?MO.;7)/7VH]A:LCE;) M$:X;T>ZBVE;0JZJ.UM4NG&;$26CWZNH6RK$Q)EW+U"^WY>T5)F1P0JY!N%/,[1(0``%7*: M'H/0!P#!7V@.IYW8_&#RYZE>M'U>=;3J&O\`7K-U+L'C!%NYMVO=X5DSCHND MD)RL%94IE0)U,0.G7IU#`-+?$/Y893[>-#E]P_YD\3=ROKM/[11ME=3A$V<$ M8;-7Z^:J'CG1YXC=I(5J?1:,W#.28"X+V',(E.`D``)//M4>,^[Y6[^13R*; M,UW/:VH7(UA/P6LVP;9(0J#]JT<24!""[:LDWG8!%W'N=@ MB!1P#3[PY\6'_*?Q!^?;1Z\$["?L&Q#VRC-)"-<-E?WRU[`6>]5G7`+6^VMXSV`."OF?Y;7"+F0EE^*.RN.],25;(: M@M=SN"$?\ZD+I1),A85N!4NH"`"GT_+TP#87QR0TLC]HAY#(UQ$R:,@L_P!\ M^PP5CWA'JW>\U\*0HM3(@NJ!A#T$I1#T']`X!JSX5_N*=:>+K@Y"<5K]Q'Y! M;1L,;LO85Z6M%.?PT3"BRN;R-5.\]K0$7H2BQ^3+A'2>>E:\4DA$V5MR#OT M6VL$558[5T6IJU9I(UJ5NR2SV;!RE&)N0AH!94WN,3F]PA2B)A$!P#0SO;ZX!L36/-[XX&?`6S^26HL;_`%_C5#[6:ZEL#R(U"UB+NYNKB08Q MS8JM1C91N9]'&6ED_P"L*.?RE/U[?B&`7_(>3GQQ[8\?KKRB2T$78_&JG$7%PX9236:=HF,D1T!`24*J`B`A@&2IKRK\'M M>\!:+Y$+=>7E`XM[`@V#JB*RU4=Q]NG%7SB1CH*HPM"BC/G#B?>JPS@J35,Q M4BIIF,8M9..9/U'C!0I5@.@(@8W:;N#NZ`98X M"^87QW>0JC<@G_'9U,U_7/':`BK3N5?9FLX[7-5BZ_8FLX])**MSNI)C(-B- MJL\,Z$R("4$?@/<3J!':G]T)X*UMJ!K3V;4E$#,!"%VZIQTBOX8D.#D&Y9;Y MH%SVXL`F814^9&']"%[NSM]<`Z=J#)4^;IU;GM?N(%[2;!#Q\_5W]7(R+7Y* M$F&Q'\=)1(QZ*#51F_:KE5(8I``P'ZX!>&`,`8`P!@#`&`,`8`P!@#`&`,`8 M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@# M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8!I%Y(-"W_E M%P4Y7\>=4SR-9V3N#2-VHU,EW#M1FV"?FHPZ;"/>.DQ*+1I-'3%DHJ(AV$<" M/PZX!_-NT58>(&N^+US\,7E0XV2'!+?R^U33U8Y[R&H&5VLU7E%+:T=IEN#% M56!LKZD%CR+QJ$E$RCR)/'G!0R8"`G$"13[BK2BO&W@'X1.'S?=YN0VKZS9[ M-'-]D)LT(9ALF!;(T]M3II-C'S-@239,:C;%6C4Q'SCJW,`@;K@'0'S'^W"X MR5^9@`($4>\2J#]Z#QU]PY3G+K"N@:\L6Y=T0%2IK6FUBZ&K5L) MMA5^>PJ,K0Y;-&B:D611M[A1$PBH'Z,`Z$/-X'&>6^VA:;,XHZ'A^.>G=VW_ M`(Z[=@]81=985)Q#NK=<6BJZDW"Q!?D6\VJBT*14Q1$H]I?7H`8!R]-SR1>,GD&(5EIO72.G>5?'5"5>B=L_D[$^U_9I)I!*F`4E4KUK]PWD4RE M$"E=1BR?ZYL`W3\H$F^=>"K[=N@+/'`U*TOKTZL$,FX71;2R\?+1<8R6=$3, M!!48M)]Z1(P@)T_F#B7IU'J!U)\O/MON-/)V:X7[7XTSU3X,VWC@G5IU:3U- MIZ,DWFP/I*U6GZ\69=L[+55&TM!/X50R4@L#Q8PNCB<#>G0#G#\UNY>/G'S[ MF-+:_*?2BW(C1U7TSJ$UTU.VK\18EK41[IQS'1ADH2=4)&.0CI9PBX,50X=" M)#T'`.B+0>O^*'DQ\/'-22\7O%Z#X36?DM3+_I)*.6J=>U]-6*T44B:T2UGE MZHX4:%B)?ZLLR27,&3RC\<7_`?D,AM9&R5 M7GG(:>96ZRUN1/:V+LR-V:.5:]/KU"0BA6B4Y)A*.H<[!HC5NL*]5ZYMTK!&.2O%5;H"YK$PV;MYB?1%F:#16O"/(G5?G1YJN6G!+3'CUU)R\ MXKP.N9U@IR/E59>1KM8<,'4W4G=E?6B6@_:ATJO5H:`=D:_4E$EWBKKL]D!- MTP#:'==*NAOO'./UP3JEI=U%EK6LM'5N2KDPI7DE1X^W]C_7)U".&+(L=VN0 MAA,J`>X<`$>OI@$5^D>;:GC$\V/E$WILWAANSD;3MG;3W'3*]'5"B_-)-U5M ML'GV\^B_L4&ZC5V3AFS["';B)CE4]!$HX!+!Y9>=`^5#[>W>&T-7\6MPZ3+5 M^4NH=6=ZE7IJN3#J=B(2N,"BA`I)3@I=2H@4AT%/T8!'CYP/&C; M=A^)SQ5IK^=?1+2//,*N:K8U7 M$>Y[TA,BD^2`W0$^N`75SSX7&;;VI=5VZ[2O$5I8K)M6@1D%*+W& M,K%HF5E?KQZV1J,\LTAY&L)E=E2;G521>E4$O:41P"XMT>5/G)YH^1'`OC]X M\=3O92(:\C[($S(UJL*,'#ZJMK-)SDG`F^F)4ZIQ46\.F:2.FZ=H[]UGK;4VK$Y6M4RJ.)?]XSR.EWU=,W:R M4C&.J\HYCGC\JRH*F$2BG^!@#`)H=7>5S>?E8X?<[M=^/7C'O+A'R6TKJVN7 MO4TS5W`[D1MSRM4Z^LH&K[TFM5HM;!&E2V&I).WR(Q<8TM1'SRM** MP"T<5F6+7*8K@QQ[.N`=\/A[T7N'C1XTN'^C=^%A0P"2K`&`,`8`P!@#`&`,`8`P! M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&` M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`^*G ML]#>[V=/R]>[I_OOR?\`"[_U?QZ_#`*?_B+ZF;I])^L]I._I\G]3[>G[/NZ? MUKM[?AU].F`5']AT-_1=O[3N_5Z?']MW?\+]?K_?P"FQ_P!`_KGTKZ/T[@^H M?3_DOUNP>GSGRW^%V=?U_P`,`]8?(]Y.GR_N_F]OKV>]\#]?;Z_M.G;W=.G^ M#\/3`/F?Z7T-[GR/3W0[^OL?TWN%Z=__`)_N=/CZ]<`_'^*.PW_$/:][\_3V M/9^8Z#_2=/V7O]/T_FP#[%^0]OT^7]GH3_>^QV]H=G3K^R]OMZ=.GY?A_S[?M^G3VOZ/MZ?AV?D]K]/3\N`>"-_=[HX^C_`$?IW&^:^F?)_K=? MS?,?*?X77X]WXX!ZQ^F]ZG=\E[O7]MW^S[G7H/3W.[\_PZ].OX?#TP#_`$GT M_P!PWM?*^[V%[_:]OW.SN_)W^W^;IW]>WK^/7IZX!X1_=WZF/7Z3];]@/_5? FK/R_Y^G_`"A[?ZW3^_@%8)V]/R_#H7]/PZ>GQ_'^?`/W@#`/_]D_ ` end